3554-93-6
Chemical Structure
Benzyl-α-GalNAc
- CAS No.: 3554-93-6
- Formula:C15H21NO6
- Molecular Weight:311.33
IUPAC Name: N-((2S,3R,4R,5R,6R)-2-(benzyloxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide
InChIKey: SKOZFDIGKDPQBO-QMIVOQANSA-N
SMILES: O[C@@H]([C@H]([C@@H](CO)O1)O)[C@@H](NC(C)=O)[C@H]1OCC2=CC=CC=C2
Biological Activity: Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-Fluorouracil (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Benzyl-α-GalNAc | 99.93% | Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-Fluorouracil (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Benzyl-α-GalNAc (Standard) | ≥98% | Benzyl-α-GalNAc (Standard) is the analytical standard of Benzyl-α-GalNAc (HY-129389). This product is intended for research and analytical applications. Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-Fluorouracil (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kalra AV, et al. Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. Br J Cancer. 2007 Oct 8;97(7):910-8. Epub 2007 Oct 2. [Content Brief]
- [2]. Kalra AV, et al. Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours. Eur J Cancer. 2009 Jan;45(1):164-73. [Content Brief]
- [3]. Fan X, et al. Protein O glycosylation regulates activation of hepatic stellate cells. Inflammation. 2013 Dec;36(6):1248-52. https://pubmed.ncbi.nlm.nih.gov/23743764/ [Content Brief]
